Pacira Pain Drug Faces FDA Delay

Xconomy New York — 

The FDA has delayed its decision on Parsippany, NJ-based Pacira Pharmaceuticals’ drug—a long-acting version of the pain drug bupivacaine called Exparel—according to a press release. Pacira, which also has operations in San Diego, went public in February, and investors pushed the company’s stock up more than 47 percent in anticipation of a July decision from the FDA. Pacira is now expecting a ruling by October 28. The company’s shares fell 14 percent to $11.30 in pre-market trading.